These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26018969)

  • 1. MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases.
    Ng CC; Tan J; Ong CK; Lim WK; Rajasegaran V; Nasir ND; Lim JC; Thike AA; Salahuddin SA; Iqbal J; Busmanis I; Chong AP; Teh BT; Tan PH
    J Clin Pathol; 2015 Sep; 68(9):685-91. PubMed ID: 26018969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent MED12 mutations in phyllodes tumours of the breast.
    Yoshida M; Sekine S; Ogawa R; Yoshida H; Maeshima A; Kanai Y; Kinoshita T; Ochiai A
    Br J Cancer; 2015 May; 112(10):1703-8. PubMed ID: 25839987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast.
    Piscuoglio S; Murray M; Fusco N; Marchiò C; Loo FL; Martelotto LG; Schultheis AM; Akram M; Weigelt B; Brogi E; Reis-Filho JS
    Histopathology; 2015 Nov; 67(5):719-29. PubMed ID: 25855048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast--implications for tumor biology and pathological diagnosis.
    Pfarr N; Kriegsmann M; Sinn P; Klauschen F; Endris V; Herpel E; Muckenhuber A; Jesinghaus M; Klosterhalfen B; Penzel R; Lennerz JK; Weichert W; Stenzinger A
    Genes Chromosomes Cancer; 2015 Jul; 54(7):444-52. PubMed ID: 25931199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MED12 exon 2 mutations in phyllodes tumors of the breast.
    Nagasawa S; Maeda I; Fukuda T; Wu W; Hayami R; Kojima Y; Tsugawa K; Ohta T
    Cancer Med; 2015 Jul; 4(7):1117-21. PubMed ID: 25865354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis of MED12 exon 2 in a spectrum of fibroepithelial tumours of the breast: implications for pathogenesis and histogenesis.
    Lien HC; Huang CS; Yang YW; Jeng YM
    Histopathology; 2016 Feb; 68(3):433-41. PubMed ID: 26109290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MED12 protein expression in breast fibroepithelial lesions: correlation with mutation status and oestrogen receptor expression.
    Tan WJ; Chan JY; Thike AA; Lim JC; Md Nasir ND; Tan JS; Koh VC; Lim WK; Tan J; Ng CC; Rajasegaran V; Nagarajan S; Bay BH; Teh BT; Tan PH
    J Clin Pathol; 2016 Oct; 69(10):858-65. PubMed ID: 27056456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways.
    Laé M; Gardrat S; Rondeau S; Richardot C; Caly M; Chemlali W; Vacher S; Couturier J; Mariani O; Terrier P; Bièche I
    Oncotarget; 2016 Dec; 7(51):84428-84438. PubMed ID: 27806318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analysis of MED12 in fibroadenomas and phyllodes tumors of the breast by means of targeted next-generation sequencing.
    Mishima C; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2015 Jul; 152(2):305-12. PubMed ID: 26093648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MED12 exon 2 and TERT promoter mutations in primary and recurrent breast fibroepithelial lesions.
    Hu Y; Li G; Wang L; Zhang L; Guan J; Wang J
    Pathol Int; 2021 Dec; 71(12):814-822. PubMed ID: 34597441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.
    Cani AK; Hovelson DH; McDaniel AS; Sadis S; Haller MJ; Yadati V; Amin AM; Bratley J; Bandla S; Williams PD; Rhodes K; Liu CJ; Quist MJ; Rhodes DR; Grasso CS; Kleer CG; Tomlins SA
    Mol Cancer Res; 2015 Apr; 13(4):613-9. PubMed ID: 25593300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of MED12 mutations in phyllodes tumors: Inverse correlation with histologic grade.
    Yoon N; Bae GE; Kang SY; Choi MS; Hwang HW; Kim SW; Lee JE; Nam SJ; Gong G; Lee HJ; Bae YK; Lee A; Cho EY
    Genes Chromosomes Cancer; 2016 Jun; 55(6):495-504. PubMed ID: 26856273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent
    Pareja F; Da Cruz Paula A; Murray MP; Hoang T; Gularte-Mérida R; Brown D; da Silva EM; Sebastiao APM; Giri DD; Weigelt B; Reis-Filho JS; Brogi E
    J Clin Pathol; 2019 Mar; 72(3):258-262. PubMed ID: 30467240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast.
    Yoshida M; Ogawa R; Yoshida H; Maeshima A; Kanai Y; Kinoshita T; Hiraoka N; Sekine S
    Br J Cancer; 2015 Oct; 113(8):1244-8. PubMed ID: 26355235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic profile of breast sarcomas: a comparison with malignant phyllodes tumours.
    Lim SZ; Ng CCY; Rajasegaran V; Guan P; Selvarajan S; Thike AA; Nasir NDBM; Koh VCY; Tan BKT; Ong KW; Teh BT; Tan PH
    Breast Cancer Res Treat; 2019 Apr; 174(2):365-373. PubMed ID: 30511242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MED12 exon 2 mutation as a highly sensitive and specific marker in distinguishing phyllodes tumours from other spindle neoplasms of the breast.
    Lien HC; Huang CS; Yang YW; Jeng YM
    APMIS; 2016 May; 124(5):356-64. PubMed ID: 26860948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic landscapes of breast fibroepithelial tumors.
    Tan J; Ong CK; Lim WK; Ng CC; Thike AA; Ng LM; Rajasegaran V; Myint SS; Nagarajan S; Thangaraju S; Dey S; Nasir ND; Wijaya GC; Lim JQ; Huang D; Li Z; Wong BH; Chan JY; McPherson JR; Cutcutache I; Poore G; Tay ST; Tan WJ; Putti TC; Ahmad BS; Iau P; Chan CW; Tang AP; Yong WS; Madhukumar P; Ho GH; Tan VK; Wong CY; Hartman M; Ong KW; Tan BK; Rozen SG; Tan P; Tan PH; Teh BT
    Nat Genet; 2015 Nov; 47(11):1341-5. PubMed ID: 26437033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MED12, TERT promoter and RBM15 mutations in primary and recurrent phyllodes tumours.
    Garcia-Dios DA; Levi D; Shah V; Gillett C; Simpson MA; Hanby A; Tomlinson I; Sawyer EJ
    Br J Cancer; 2018 Jan; 118(2):277-284. PubMed ID: 29315289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations.
    Otsuji K; Sasaki T; Tanabe M; Seto Y
    Br J Cancer; 2021 Jan; 124(2):466-473. PubMed ID: 33046803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Size and heterologous elements predict metastases in malignant phyllodes tumours of the breast.
    Koh VCY; Thike AA; Nasir NDM; Yip GWC; Bay BH; Tan PH
    Virchows Arch; 2018 Apr; 472(4):615-621. PubMed ID: 29127495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.